Latest Conference Articles

Ciaran P. Kelly, Associate Professor, Harvard Medical School discusses common and uncommon issues related to swallowing.

How does video teleconferencing compare to face-to-face visits in the eyes of parents of psychiatric patients?

This symposium included presentations of NNT and NNH analyses of approved pharmacotherapies for various phases of bipolar disorder

This symposium presented five novel applications of IPSRT.

This symposium focused on presenting the most recent results of key projects conducted to evaluate the effects of early detection/intervention strategies.

Falls remain the most commonly documented adverse event in the hospital setting.

A session at ONS discussed intergenerational differences in nursing.

The need to eliminate the trial-and-error approach to vein hunting inspired the creation of VeinViewer in 2006.

Paula Trahan Rieger, RN, MSN, CAE, FAAN, is the CEO of ONS and has received numerous awards throughout a storied career.

ONS kicked off with a lively parade, which included over 100 nurses representing 16 countries from all over the globe.

Risk evaluation Mitigation Strategies may be the latest program designed to alter the rate of abuse and misuse of prescription drugs.

Virtual reality is an effective tool not only for distracting children during acute procedures, but also for the management of recurrent or cronic pain.

The pros and cons of using the hemoglobin A1C test to diagnose prediabetes and diabetes was the subject of a lively debate at the AACE Meeting.

In a preliminary study, Attiva, increased the post-meal feeling of satiety and reduced hunger between meals.

New research released today at the AACE Meeting indicates another reason to avoid fast food; it may also be lacking in appropriate amounts of iodine.

A novel mitral valve clip was proven to be as safe and effective as open-chest surgery in selected patients with mitral valve regurgitation.

New treatments are desperately needed for neuroendocrine tumors, said Leonard Saltz, MD, Memorial Sloan-Kettering Cancer Center.

Gardasil, a vaccine that prevents cervical cancer, also reduces the likelihood of recurrence after surgery by 40%.

Recent court rulings have grown in prominence because the Obama administration has taken a more tolerant stance toward the use of medical marijuana.

To improve early detection of colorectal cancer and adenomas, when survival chances are greatest, researchers tried develop a reliable blood test for detection.

Updated results confirm that addition of bevacizumab to docetaxel as first-line breast cancer treatment improves survival and response rates.

Letrozole treatment over 5 years was still associated with significantly better overall survival than 5 years with tamoxifen.

During the 51st ASH Annual Meeting, several new data from the PROPEL trial were released, including updates on the ORR and safety of pralatrexate in patients with PTCL and data on the correlation between baseline methylmalonic acid status and mucositis severity in this population. While the data reinforce pralatrexate as a viable treatment in patients with relapsed or refractory PTCL, some question whether the drug confers enough of a benefit to warrant its $30,000 per month cost.

Several studies have been examining various 3- and even 4-drug regimens in patients with newly diagnosed multiple myeloma. Paul G. Richardson, MD, and colleagues from the Dana-Farber Cancer Institute in Boston, Massachusetts, conducted a phase I/II study investigated the novel combination of lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (Decadron). In an interview with Oncology & Biotech News/Oncology NetGuide, Dr Richardson said response was “unprecedented.” In presenting data from the studies, Dr Richardson said, “Partial responses or better were seen in all of the 66 patients treated with the drug combination…with 74% having a VGPR rate in the phase II portion.” He added that the 54% rate of CR/near CR in patients enrolled in the phase II study “was also encouraging.”

Single-agent pixantrone, an investigational agent, showed encouraging third-line responses, duration of responses, and progression-free survival (PFS) compared with other single-agent chemotherapies in patients with relapsed aggressive non-Hodgkin lymphoma (NHL) in the phase III, randomized, open-label, multicenter EXTEND trial. In the study, patients with relapsed/refractory NHL treated with pixantrone achieved significant increases in complete response (CR) and overall response (ORR) and demonstrated a positive trend in overall survival (OS) compared with other chemotherapy agents, according to Ruth Pettengell, MD, of St. Georges Hospital in London, who presented these results at a poster session. “An anthracycline with reduced cardiotoxicity that can be used for salvage therapy of aggressive NHL meets a significant unmet medical need,” she said.